Novel Macrocyclic NLRP3 Inhibitors.

Area of Science:

• Medicinal Chemistry
• Immunology
• Pharmacology

Background:

• Aberrant activation of the NLRP3 inflammasome is implicated in numerous chronic inflammatory disorders, including cryopyrin-associated periodic syndrome (CAPS), neurodegenerative diseases, and gouty arthritis.
• There is a significant therapeutic interest in developing NLRP3 inhibitors to manage these conditions.
• First-generation inhibitors, like MCC950, were identified via phenotypic screening, with their mechanisms elucidated later.

Purpose of the Study:

• To discover and optimize novel macrocyclic NLRP3 inhibitors.
• To address limitations of previous inhibitor generations, such as moderate potency and potential drug-induced liver injury.
• To explore structure-activity relationships leading to improved NLRP3 inhibition.

Main Methods:

• Utilized conformational studies during the optimization of second-generation NLRP3 inhibitors.
• Designed and synthesized novel macrocyclic compounds based on insights from MCC950 optimization.
• Evaluated the inhibitory properties and potential therapeutic applications of the newly developed macrocycles.

Main Results:

• Successfully designed and optimized a novel class of macrocyclic NLRP3 inhibitors.
• These macrocycles represent a new generation of NLRP3 inhibitors with potentially improved pharmacological profiles.
• The study details the discovery and optimization process for this promising therapeutic class.

Conclusions:

• The discovery of these macrocyclic NLRP3 inhibitors offers a promising new avenue for treating chronic inflammatory diseases.
• Further development of this class could lead to more effective and safer therapeutics for NLRP3-mediated conditions.
• This work highlights the value of structure-based design in advancing drug discovery for inflammasome inhibitors.